Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Oslo, Norway, 9 October 2019 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with [212]Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European Association of Nuclear Medicine (12-16 October, Barcelona, Spain). In the study, the efficacy of [212]Pb-NNV003 was compared with ibrutinib in a disseminated mouse model using the ibrutinib-resistant cell line MEC-2. Ibrutinib is a Bruton’s tyrosine kinase (